Money Concepts Capital Corp Sells 4,126 Shares of Gilead Sciences, Inc. $GILD

Money Concepts Capital Corp trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 86,105 shares of the biopharmaceutical company’s stock after selling 4,126 shares during the quarter. Gilead Sciences comprises about 0.6% of Money Concepts Capital Corp’s portfolio, making the stock its 29th biggest holding. Money Concepts Capital Corp’s holdings in Gilead Sciences were worth $10,568,000 as of its most recent filing with the SEC.

Other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC lifted its position in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares during the last quarter. Bison Wealth LLC bought a new stake in shares of Gilead Sciences during the 4th quarter worth $215,000. Sivia Capital Partners LLC lifted its position in shares of Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after buying an additional 602 shares during the last quarter. Ieq Capital LLC lifted its position in shares of Gilead Sciences by 12.0% during the 2nd quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock worth $13,160,000 after buying an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC lifted its position in shares of Gilead Sciences by 18.6% during the 2nd quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $516,000 after buying an additional 674 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on GILD shares. Oppenheimer upped their price objective on Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Rothschild & Co Redburn dropped their price objective on Gilead Sciences from $170.00 to $167.00 in a research report on Monday. Morgan Stanley dropped their price objective on Gilead Sciences from $175.00 to $168.00 in a research report on Friday. Scotiabank upped their price objective on Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, February 11th. Finally, Citigroup upped their price objective on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $157.04.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead delivered Q1 revenue of $6.96 billion, up 4.4% year over year and ahead of expectations, while adjusted EPS of $2.03 also beat consensus. Management said full-year revenue should come in around $30.2 billion, roughly in line with Wall Street estimates, which supports the view that core operations remain stable. Article: GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook
• Positive Sentiment: Analysts continue to see upside from Gilead’s HIV business and oncology pipeline, and Truist recently reiterated a Buy rating, which can help reinforce investor confidence in the stock. Article: Gilead Sciences Earns Buy Rating from Truist Financial
• Neutral Sentiment: Several firms have updated valuation models after the earnings release, including Rothschild & Co Redburn trimming its price target to $167 and RBC lowering its target to $122, reflecting a mixed analyst reaction rather than a clear shift in the long-term thesis. Article: Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences to $167 from $170
• Negative Sentiment: The biggest concern is Gilead’s sharply reduced fiscal 2026 EPS outlook, which now calls for a loss of $1.05 to $0.65 per share after accounting for about $11.5 billion in IPR&D and financing costs. That guidance cut is likely the main reason shares are facing pressure despite the earnings beat. Article: Gilead Sciences, Inc. (GILD) Outlook Cut Sharply on $11.5B IPR&D and Financing Costs

Gilead Sciences Price Performance

Gilead Sciences stock opened at $133.52 on Tuesday. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The company has a market capitalization of $165.77 billion, a PE ratio of 18.19 and a beta of 0.31. Gilead Sciences, Inc. has a 12 month low of $96.18 and a 12 month high of $157.29. The stock has a 50-day moving average price of $139.07 and a two-hundred day moving average price of $132.99.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period last year, the company earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Analysts expect that Gilead Sciences, Inc. will post -0.85 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be given a $0.82 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total value of $4,324,320.00. Following the completion of the transaction, the insider directly owned 120,288 shares in the company, valued at approximately $18,577,278.72. This trade represents a 18.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00. Following the completion of the sale, the chief executive officer directly owned 632,567 shares of the company’s stock, valued at approximately $81,702,353.72. The trade was a 1.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 63,000 shares of company stock worth $9,238,250. 0.30% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.